KIR2DS5: A Potential Drug Target and Biomarker for Immune and Cancers
KIR2DS5: A Potential Drug Target and Biomarker for Immune and Cancers
Killer cell immunoglobulin-like receptor 2DS5 (KIR2DS5) is a protein that is expressed in various tissues and cell types in the human body. It is a member of the killer cell immunoglobulin-like receptor (KIR) family, which is a subfamily of the immunoglobulin receptor (IgR) family. KIRs are involved in the immune response and play a crucial role in the regulation of cell proliferation and differentiation.
The KIR2DS5 protein is a type of KIR that is expressed in natural killer (NK) cells, which are a crucial part of the immune system. NK cells are a subset of T cells that are involved in the elimination of infected or abnormal cells in the body. KIR2DS5 is thought to be involved in the regulation of NK cell function and has been shown to play a role in the development and maintenance of NK cell tolerance.
KIR2DS5 is also expressed in other cell types, including epithelial cells, endothelial cells, and pericytes. It is also expressed in various tissues and organs, including the skin, gut, and blood vessels. KIR2DS5 has been shown to be involved in the regulation of cell adhesion, migration, and survival.
Drug Target Potential
KIR2DS5 is a potential drug target due to its involvement in the immune response and its expression in various cell types. Its role in NK cell function and its expression in various tissues make it an attractive target for therapeutic intervention.
One potential approach to targeting KIR2DS5 is to use small molecules that can modulate its expression and activity. Small molecules that can interact with KIR2DS5 include inhibitors of tyrosine kinase, inhibitors of phosphorylation, and modulators of protein-protein interactions.
Another potential approach to targeting KIR2DS5 is to use antibodies that can specifically recognize and target it. Antibodies that recognize KIR2DS5 include monoclonal antibodies (MCABs), which are antibodies produced by a single cell, and polyclonal antibodies (PCABs), which are antibodies produced by a large number of cells.
KIR2DS5 has also been shown to be involved in the regulation of cell adhesion and migration. Antibodies that recognize KIR2DS5 and can modulate its activity may be useful in treating diseases that are characterized by the disruption of cell adhesion and migration, such as cancer.
Biomarker Potential
KIR2DS5 has also been shown to be involved in the regulation of cell proliferation and differentiation. Its expression in various tissues and cell types makes it an attractive biomarker for the diagnosis and monitoring of cancer.
Monoclonal antibodies (MCABs) that recognize KIR2DS5 may be useful in detecting the presence of cancer cells in various tissues, including cancerous tumors. These antibodies can also be used to evaluate the effectiveness of therapeutic interventions in cancer treatment.
Conclusion
KIR2DS5 is a protein that is involved in the regulation of various cellular processes in the body. Its expression in NK cells and other cell types makes it an attractive target for therapeutic intervention. Small molecules and antibodies that can modulate its expression and activity may be useful in treating diseases that are characterized by the disruption of cell adhesion and migration, such as cancer. As further research is conducted, it is likely that the role of KIR2DS5 in the immune response and its expression in various tissues will continue to be discovered and understood.
Protein Name: Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 5
Functions: Activating natural killer (NK) receptor that recognizes C2 epitopes of HLA-C alleles. Bridging the innate and adaptive immune systems, NK cells express a number of cell surface receptors which either inhibit or stimulate their cytotoxicity (PubMed:28685972, PubMed:18624290, PubMed:18682925). Able to activate NK cells citotoxicity and cytokine production such as IFNG (PubMed:18624290, PubMed:24269691). Receptor functions are attenuated even lost in some alleles, such as KIR2DS5*002 reprensented in this entry (PubMed:28685972)
More Common Targets
KIR3DL1 | KIR3DL2 | KIR3DL3 | KIR3DP1 | KIR3DS1 | KIR3DX1 | KIRREL1 | KIRREL1-IT1 | KIRREL2 | KIRREL3 | KIRREL3-AS2 | KIRREL3-AS3 | KISS1 | KISS1R | KIT | KITLG | KIZ | KIZ-AS1 | KL | KLB | KLC1 | KLC2 | KLC3 | KLC4 | KLF1 | KLF10 | KLF11 | KLF12 | KLF13 | KLF14 | KLF15 | KLF16 | KLF17 | KLF17P1 | KLF2 | KLF3 | KLF3-AS1 | KLF4 | KLF5 | KLF6 | KLF7 | KLF8 | KLF9 | KLHDC1 | KLHDC10 | KLHDC2 | KLHDC3 | KLHDC4 | KLHDC7A | KLHDC7B | KLHDC7B-DT | KLHDC8A | KLHDC8B | KLHDC9 | KLHL1 | KLHL10 | KLHL11 | KLHL12 | KLHL13 | KLHL14 | KLHL15 | KLHL17 | KLHL18 | KLHL2 | KLHL20 | KLHL21 | KLHL22 | KLHL23 | KLHL24 | KLHL25 | KLHL26 | KLHL28 | KLHL29 | KLHL3 | KLHL30 | KLHL30-AS1 | KLHL31 | KLHL32 | KLHL33 | KLHL34 | KLHL35 | KLHL36 | KLHL38 | KLHL4 | KLHL40 | KLHL41 | KLHL42 | KLHL5 | KLHL6 | KLHL7 | KLHL7-DT | KLHL8 | KLHL9 | KLK1 | KLK10 | KLK11 | KLK12 | KLK13 | KLK14 | KLK15